文献速递心律失常心力衰竭与心肌病

室性早搏的评估与管理

Evaluation and Management of Premature Ventricular Complexes.
PubMed 文献 · Circulation · 2020-04-27

本文综述室性早搏(PVC)的流行病学、机制、诊断评估与治疗策略。PVC在长期动态监测中常见,频率与年龄、身高、血压、心脏病史、体力活动少和吸烟相关。无症状且负荷低、心功能正常者可仅予安慰;有症状或左室射血分数降低者,药物治疗或导管消融均为一线选择,患者偏好影响首选方案。

要点

  • 多数PVC无症状,有症状者可表现为心悸、呼吸困难、先兆晕厥和乏力。
  • 症状或频繁PVC时行超声心动图,疑结构性心脏病时考虑心脏磁共振。
  • 无症状、低负荷且心功能正常者仅需安慰,无需积极干预。

核心结论

  • PVC常见且预后不一,频率增加可能是心衰和死亡的危险因素,导管消融后收缩功能恢复提示可能存在因果关系。

研究设计与样本

  • 综述,总结PVC的评估与管理,未报告系统检索范围或样本量。

主要发现

  • 年龄增长、身高较高、血压较高、心脏病史、体力活动较少和吸烟均预测PVC频率更高。
  • PVC机制包括触发活动、自律性和折返,根本原因仍 largely unknown。
  • PVC负荷增加可能是心衰和死亡的危险因素,消融后收缩功能恢复提示因果关系。

关键数值与推荐

  • 有症状或PVC特别频繁时行超声心动图,评估提示结构性心脏病时行心脏磁共振。
  • 需动态监测评估PVC频率。
  • 无症状或轻微症状、低PVC负荷且心室功能正常者可仅予安慰。
  • 有症状或左室射血分数降低者,药物治疗或导管消融为一线,患者偏好影响首选。
  • 室收缩功能正常者,β受体阻滞剂或非二氢吡啶类钙通道阻滞剂为合理药物。

临床怎么用

  • 根据症状、PVC负荷和左室功能分层管理:低危者安慰,有症状或心功能降低者选择药物或消融。
  • 初始药物失败且消融被拒绝、不成功或不合适时,考虑其他抗心律失常药。
  • 导管消融根除PVC最有效,但 upfront 风险可能增加。

局限性

  • PVC根本原因仍 largely unknown。
  • 不良结局最有信息量的预测因素仍不确定。
  • 需原创研究识别PVC诱导心肌病风险个体及针对根源的预防和治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Premature ventricular complexes (PVCs) are extremely common, found in the majority of individuals undergoing long-term ambulatory monitoring. Increasing age, a taller height, a higher blood pressure, a history of heart disease, performance of less physical activity, and smoking each predict a greater PVC frequency. Although the fundamental causes of PVCs remain largely unknown, potential mechanisms for any given PVC include triggered activity, automaticity, and reentry. PVCs are commonly asymptomatic but can also result in palpitations, dyspnea, presyncope, and fatigue. The history, physical examination, and 12-lead ECG are each critical to the diagnosis and evaluation of a PVC. An echocardiogram is indicated in the presence of symptoms or particularly frequent PVCs, and cardiac magnetic resonance imaging is helpful when the evaluation suggests the presence of associated structural heart disease. Ambulatory monitoring is required to assess PVC frequency. The prognosis of those with PVCs is variable, with ongoing uncertainty regarding the most informative predictors of adverse outcomes. An increased PVC frequency may be a risk factor for heart failure and death, and the resolution of systolic dysfunction after successful catheter ablation of PVCs demonstrates that a causal relationship can be present. Patients with no or mild symptoms, a low PVC burden, and normal ventricular function may be best served with simple reassurance. Either medical treatment or catheter ablation are considered first-line therapies in most patients with PVCs associated with symptoms or a reduced left ventricular ejection fraction, and patient preference plays a role in determining which to try first. If medical treatment is selected, either β-blockers or nondihydropyridine calcium channel blockers are reasonable drugs in patients with normal ventricular systolic function. Other antiarrhythmic drugs should be considered if those initial drugs fail and ablation has been declined, has been unsuccessful, or has been deemed inappropriate. Catheter ablation is the most efficacious approach to eradicate PVCs but may confer increased upfront risks. Original research remains necessary to identify individuals at risk for PVC-induced cardiomyopathy and to identify preventative and therapeutic approaches targeting the root causes of PVCs to maximize effectiveness while minimizing risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Marcus GM. Evaluation and Management of Premature Ventricular Complexes. Circulation. 2020. PMID: 32339046. doi:10.1161/CIRCULATIONAHA.119.042434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。